Vascular Closure Device Market – By Device Type (Active [Suture-Mediated, Staple Clips-Mediated, Collagen Plug-Mediated], Passive [Haemostasis Pads/Patches, Compression Devices]), Access (Femoral, Radial), End-use (Hospitals) & Forecast, 2024 – 2032

Vascular Closure Device Market Size

Vascular Closure Device Market size was valued at USD 1.7 billion in 2023 and is expected to exhibit growth at a CAGR of 6.3% from 2024 to 2032. High market growth can be attributed to the ongoing advancements in medical technology, increasing prevalence of cardiovascular diseases, rising demand for minimally invasive procedures, and expanding healthcare expenditure, among other contributing factors.

Moreover, the global rise in the prevalence of cardiovascular diseases, such as coronary artery disease, peripheral interventions disease, and stroke, has led to an increase in diagnostic and therapeutic catheterization procedures. For instance, according to the British Heart Foundation, in 2024, there are around 620 million people living with heart and circulatory diseases across the world. VCDs are essential in managing the access sites used in these procedures, as they help achieve hemostasis quickly and efficiently. The growing number of cardiovascular interventions directly fuels the demand for vascular closure devices.
 

Furthermore, rising healthcare expenditure, particularly in developing regions, has led to the modernization of healthcare infrastructure and increased access to advanced medical technologies. Improved healthcare facilities and increased investment in cardiovascular care drive the adoption of vascular closure devices, contributing to market growth.
 

Vascular closure device is a medical device used to achieve hemostasis at the access site following a vascular procedure, such as angiography or angioplasty. It facilitates the sealing of the puncture site in an artery, typically the femoral or radial artery, to prevent bleeding and promote quicker patient recovery. VCDs offer an alternative to manual compression methods, improving patient comfort and reducing complications.
 

Vascular Closure Device Market Trends

The vascular closure device market is experiencing several notable trends that are shaping its growth and development. Factors such as continuous innovations in design and material, rise of minimally invasive treatments, growing adoption of radial access procedures, and surging need for integrated medical imaging technologies, among other factors are propelling the industry growth.
 

• Continuous innovation in the design and functionality of VCDs is a major trend. This includes the development of bioabsorbable materials, which reduce the risk of long-term complications, and the integration of advanced sealing mechanisms that enhance device efficacy and safety. These advancements lead to improved patient outcomes and broaden the adoption of VCDs in clinical practice.
   
• Further, there is an increasing focus on improving patient safety and outcomes in healthcare. VCDs contribute to this by providing reliable and quick hemostasis, reducing the risk of complications such as bleeding, hematoma, and infection. This focus enhances the adoption of VCDs in clinical practice, thereby aforementioned factors are expected to drive the market.
   

Vascular Closure Device Market Analysis

Based on device type, the market is classified into active vascular closure devices and passive vascular closure devices. The active vascular closure devices segment is further bifurcated into suture-mediated devices, staple clips-mediated vascular closure devices, and collagen plug-mediated devices. The passive segment is further divided into haemostasis pads/patches, and compression devices. The active vascular closure devices segment generated the highest revenue of USD 987.7 million in 2023.
 

• Active VCDs incorporate advanced technologies that enhance their performance and reliability. Innovations such as bioabsorbable materials, improved sealing mechanisms, and automated deployment systems reduce the risk of complications and ensure consistent closure of vascular access sites. These technological improvements make active VCDs more effective and safer compared to passive or manual compression methods.
   
• Moreover, it provide quicker and more reliable hemostasis, which translates to better patient outcomes. By reducing the time to achieve hemostasis, it also minimize the risk of bleeding, hematoma, and infection at the access site. This rapid closure allows for earlier patient mobilization and discharge, enhancing overall patient satisfaction and recovery.
   

Based on access, the vascular closure device market is classified into femoral, and radial. The femoral segment dominated the market in 2023 with a market share of 84%.
 

• The femoral artery is frequently used as an access site for a wide range of diagnostic and interventional cardiovascular procedures, including angiography, angioplasty, and stent placement. The high volume of these procedures necessitates the use of reliable and effective closure devices to manage the access site, driving demand for femoral in market.
   
• Furthermore, it significantly reduce the time required to achieve hemostasis compared to manual compression methods. This reduction in procedure time translates to increased procedural efficiency and lower overall healthcare costs. Shorter procedure times allow for a higher throughput of patients, benefiting both healthcare providers and patients by reducing hospital stays and associated costs.
   

Based on end-use, the vascular closure device market is segmented into hospitals, ambulatory surgical centers, and other end-users. The hospitals segment dominated the market in 2023 and is anticipated to reach USD 1.8 billion by the end of forecast period.
 

• Hospitals are increasingly focusing on patient satisfaction as a key performance metric. The use of VCDs contributes to higher patient satisfaction by reducing complications, minimizing recovery times, and improving overall procedural outcomes, making them a valuable tool in hospital care.
   
• Additionally, the integration of hybrid operating rooms, which combine surgical and interventional capabilities, is becoming more common in hospitals. These advanced facilities require efficient vascular closure solutions to manage access sites during complex procedures.
   

North America vascular closure device market accounted for USD 751.1 million market revenue in 2023 and is anticipated to grow at CAGR of 6.1% between 2024 – 2032 period.
 

• North America has a significant prevalence of cardiovascular diseases. These conditions necessitate a large number of diagnostic and interventional cardiovascular procedures, which often require vascular access and subsequent closure using these devices.
   
• Moreover, the region has one of the highest healthcare expenditures globally, with substantial investments in advanced medical technologies and devices. The availability of healthcare funding and insurance coverage supports the adoption of innovative medical devices in clinical practice, ensuring access for patients and healthcare providers.
   
• For instance, according to the data by Centers for Medicare and Medicaid Services (CMS.gov) shows that in 2023, the U.S. spent approximately USD 4.7 trillion on healthcare, constituting 18% of the national economy. It is projected that total healthcare expenses, including private and governmental spending, will increase from USD 4.7 trillion in 2023 to USD 7.2 trillion by 2031, with an average growth rate of 5.5% per year.
   

Germany vascular closure device market is projected to grow remarkably in the coming years.
 

• Germany has a well-developed healthcare infrastructure, including state-of-the-art hospitals, specialized cardiovascular centers, and research institutions. The availability of advanced imaging technologies, robotic-assisted surgeries, and hybrid operating rooms supports the integration of VCDs into clinical practice. These facilities enable healthcare providers to utilize such devices effectively, enhancing procedural outcomes and patient care.
   
• Additionally, healthcare reforms and policies in country aim to improve healthcare delivery, enhance patient outcomes, and optimize healthcare expenditures. VCDs, by offering efficient vascular closure solutions, align with these objectives by improving procedural efficiency, reducing hospital stays, and minimizing healthcare costs associated with post-procedural complications.
   

Japan holds a dominant position in the Asia Pacific vascular closure device market.
 

• Japan has one of the oldest populations globally, leading to an increased incidence of age-related cardiovascular conditions. The aging demographic drives the demand for cardiovascular procedures and interventions, wherein VCDs contribute to improved patient outcomes and management of vascular access complications in elderly patients.
   
• Furthermore, the Japanese society has a strong cultural acceptance of technological advancements in healthcare. This acceptance facilitates the adoption of advanced medical devices, as healthcare providers and patients alike value innovation that enhances treatment outcomes and patient care.
   

Vascular Closure Device Market Share

The market is characterized by the presence of several key players and a focus on technological innovation and strategic partnerships. These companies invest significantly in research and development to introduce advanced VCD technologies, including bioabsorbable devices, hemostatic plugs, and closure systems with enhanced safety features. Market competition is intensified by stringent regulatory requirements and the need for continuous product enhancements to meet evolving clinical needs. Strategic initiatives such as mergers, acquisitions, and collaborations are common strategies employed by key players to strengthen their market position and expand their geographic footprint. Emerging players also play a crucial role in the market by introducing innovative solutions aimed at improving procedural outcomes and patient care in vascular access management.
 

Vascular Closure Device Market Companies

Prominent players operating in the vascular closure device industry include:

• Abbott Laboratories
• Advanced Vascular Dynamics
• Biotronik SE & Co. KG
• Cardinal Health, Inc.
• Ensite Vascular
• Haemonetics Corporation (cardiva Medical Inc.)
• Marine Polymer Technologies
• Medtronic, Plc
• Merit Medical Systems
• REX MEDICAL
• Teleflex Incorporated
• Terumo Corporation
• Tricol Biomedical
• TZ Medical
• Vasorum Limited
   

Vascular Closure Device Industry News:

• On July 2024, Cordis announced that its MYNX CONTROL VENOUS vascular closure device (VCD) has received PMA clearance from the U.S. Food and Drug Administration (FDA) for operations with access sites ranging from 6F to 12F. This provides Cordis with an array of extravascular closure devices, which are intended for predictable deployment and ease of use.
   
• In June 2024, Haemonetics Corporation has announced the launch of its new VASCADE MVP XL mid-bore venous closure device. The VASCADE MVP XL system adds to Haemonetics VASCADE line of vascular closure devices by using novel collapsible disc technology with a patented resorbable collagen patch that promotes fast hemostasis.
   

The vascular closure device market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Device Type

• Active vascular closure devices
  • Suture-mediated devices
  • Staple clips-mediated vascular closure devices
  • Collagen plug-mediated devices
• Passive vascular closure devices
  • Haemostasis pads/patches
  • Compression devices

Market, By Access

• Femoral
• Radial

Market, By End-use

• Hospitals
• Ambulatory surgical centers
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Poland
  • Sweden
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Indonesia
  • Philippines
  • Vietnam
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Turkey
  • Israel
  • Iran
  • Rest of Middle East and Africa